Eton Pharmaceuticals

Yahoo Finance • last year

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in positive cash flow from operations; ended qu... Full story

Yahoo Finance • last year

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients sufferin... Full story

Yahoo Finance • last year

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

-- Expect Q1 2024 product launch -- -- Nitisinone market estimated to be more than $50 million annually -- -- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharma... Full story

Yahoo Finance • last year

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelse... Full story

Yahoo Finance • last year

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the U.S. Food... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Et... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

-- Product is targeting rare pediatric endocrinology condition -- -- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innov... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will repo... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results

Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product, Betaine Anhydrous, added to rare disease p... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will repor... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announce... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announce... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on rare disease strategyU.S. Food and Dru... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will repor... Full story

Yahoo Finance • 2 years ago

Eton's stock gains 16% after announcing FDA approval of epilepsy drug

Shares of Eton Pharmaceuticals Inc. jumped 16.5% in premarket trading on Monday after the company said the Food and Drug Administration approved Zonisade, a seizure treatment for adults and teens older than 16 years old with epilepsy. Per... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food... Full story

Yahoo Finance • 2 years ago

Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseasesEton’s royalty... Full story

Yahoo Finance • 3 years ago

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for... Full story

Yahoo Finance • 3 years ago

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report... Full story

Yahoo Finance • 3 years ago

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

Eton Pharmaceuticals DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announce... Full story